KLOW Blend Peptide

KLOW Blend Peptide Molecular Structure & Chemical Properties

KLOW Blend represents an advanced synergistic combination of four extensively studied regenerative and anti-inflammatory peptides – BPC-157, TB-500, GHK-Cu, and KPV – developed to provide comprehensive tissue repair, inflammation control, and regenerative effects in preclinical research models. This peptide formulation builds upon the foundation of the three-component GLOW Blend by incorporating KPV, a potent anti-inflammatory tripeptide that addresses inflammatory pathways through distinct mechanisms. The combination leverages complementary properties: BPC-157’s gastric acid resistance and multi-organ cytoprotection, TB-500’s actin-sequestering and cell migration capabilities, GHK-Cu’s copper-mediated matrix remodeling and gene expression modulation, and KPV’s targeted NF-kappaB inhibition for inflammation control. This four-peptide system was designed to investigate comprehensive healing responses that address not only tissue regeneration but also the inflammatory component that often impairs optimal repair.

Chemical Composition

Representative component structure of individual component peptides – blend contains four distinct peptides (Source: PubChem)

Technical Specifications

The blend combines four distinct peptide classes: a gastric-derived pentadecapeptide (BPC-157), an actin-sequestering peptide (TB-500), a copper-binding tripeptide (GHK-Cu), and an anti-inflammatory tripeptide (KPV), creating a comprehensive research tool that addresses tissue regeneration, cellular migration, matrix remodeling, and inflammation control simultaneously.

KLOW Blend Peptide Mechanism of Action

KLOW Blend exerts its biological effects through four complementary but distinct molecular pathways that work synergistically to promote tissue repair, control inflammation, enhance angiogenesis, and support cellular regeneration. Rather than targeting a single receptor or pathway, this advanced peptide combination activates multiple interconnected signaling networks while simultaneously suppressing inflammatory cascades that can impair healing, creating a comprehensive regenerative environment beyond what individual components might achieve alone.

Primary Cellular Pathways

FAK/Paxillin Signaling – Cell Migration and Adhesion

BPC-157 significantly increases phosphorylation of focal adhesion kinase (FAK) and paxillin proteins in fibroblast cells, promoting enhanced cell adhesion and migration[1]. This pathway activation enables:

• Accelerated migration of repair cells to injury sites
• Improved cell survival under oxidative stress conditions
• Enhanced F-actin formation essential for cellular movement
• Increased fibroblast outgrowth and spreading capacity

Research using FITC-phalloidin staining demonstrated that BPC-157 potently stimulates F-actin formation, working synergistically with TB-500’s actin-sequestering functions to provide comprehensive cytoskeletal support for cellular mechanics throughout the healing process.

Actin Sequestration and Cytoskeletal Remodeling

TB-500 functions as the primary actin-sequestering molecule in the blend, binding globular actin (G-actin) and regulating actin polymerization[2]. This mechanism involves:

• Control of actin filament assembly and disassembly
• Enhanced cellular migration through cytoskeletal reorganization
• Improved cell morphological changes during repair processes
• Regulation of cellular mechanical properties enabling tissue remodeling

The peptide’s actin-binding domain (LKKTET sequence) allows precise modulation of cytoskeletal dynamics, enabling cells to migrate more effectively to sites requiring repair while coordinating with BPC-157’s FAK activation for optimal cellular movement.

NF-kappaB Pathway Inhibition – Targeted Anti-Inflammatory Control

KPV provides potent anti-inflammatory effects through direct inhibition of nuclear factor-kappa B (NF-kappaB), distinguishing KLOW from GLOW through enhanced inflammation control[3]:

• Competitive blocking of importin-alpha3 interaction with NF-kappaB p65/RelA subunit
• Prevention of NF-kappaB nuclear translocation in activated cells
• Inhibition of pro-inflammatory gene transcription
• Reduction of cytokine production including TNF-alpha, IL-1beta, and IL-6
• PepT1-mediated cellular uptake enabling intracellular anti-inflammatory action

This mechanism operates at nanomolar concentrations and works through a melanocortin receptor-independent pathway, providing inflammation control without hormonal side effects while complementing the other components’ regenerative actions.

Copper-Mediated Matrix Remodeling and Gene Expression

GHK-Cu promotes extracellular matrix synthesis and remodeling through copper-dependent enzymatic activation and broad genomic effects[4]:

• Stimulation of collagen and elastin synthesis in fibroblasts
• Activation of lysyl oxidase for collagen cross-linking
• Enhanced production of glycosaminoglycans and decorin
• Modulation of metalloproteinase activity for controlled matrix breakdown
• Gene expression changes affecting over 30% of human genes, resetting cellular programs toward regenerative states

The copper ion serves as an essential cofactor for enzymes involved in collagen synthesis and provides antioxidant protection through superoxide dismutase activation, while the peptide itself influences gene transcription to support healing.

Angiogenic Pathway Activation – Multi-Component Blood Vessel Formation

Multiple components contribute to comprehensive angiogenesis through distinct but complementary mechanisms[5]:

• BPC-157 upregulates VEGFR2 expression and enhances endothelial cell proliferation
• TB-500 promotes endothelial cell migration and tube formation
• GHK-Cu stimulates angiogenic growth factor expression and vessel maturation
• Combined effects result in robust tissue vascularization and nutrient delivery
• Improved collateral circulation development in ischemic conditions

Nitric Oxide System Modulation – Vascular Protection

BPC-157 influences nitric oxide signaling pathways to support vascular function[6]:

• Enhanced eNOS phosphorylation leading to controlled NO production
• Modulation of blood flow and vascular tone
• Protection against both NO excess and NO deficiency states
• Coordination with angiogenic effects for comprehensive vascular support

KLOW Blend Research Applications & Key Findings

Inflammatory Bowel Disease and Gastrointestinal Research

Enhanced Mucosal Protection and Healing

The combination of BPC-157’s gastroprotective effects with KPV’s targeted intestinal anti-inflammatory action provides comprehensive gastrointestinal support. BPC-157 research has extensively documented mucosal healing and cytoprotection[7], while KPV studies demonstrated significant reduction of colitis severity in multiple rodent models[8]:

• BPC-157 component: Healing acceleration in NSAID-induced gastric ulcers and stress-induced damage
• KPV component: Reduced inflammatory cell infiltration and lower MPO activity in DSS-induced colitis
• Combined potential: Addresses both tissue damage and inflammatory pathways simultaneously
• Fistula healing demonstrated in BPC-157 studies with potential inflammatory control from KPV
• PepT1-mediated KPV uptake enables targeted delivery to inflamed intestinal tissues

Research on individual components suggests the combination may provide superior outcomes by healing damaged tissue while actively suppressing inflammatory cascades that impair repair[9].

Intestinal Barrier Function Enhancement

Component research revealed complementary barrier-protective mechanisms:

• BPC-157 maintains mucosal integrity under various injurious conditions
• KPV protects mucosal barrier function and reduces epithelial permeability
• TB-500 promotes epithelial cell migration for wound closure
• GHK-Cu supports collagen synthesis for structural integrity

Musculoskeletal Tissue Research

Comprehensive Tendon and Ligament Healing

Research investigating individual components has demonstrated significant synergistic potential for connective tissue repair. BPC-157 studies in rat models showed accelerated healing in Achilles tendon transection with improved biomechanical properties[10]. Key findings across components include:

• BPC-157: Enhanced load-to-failure measurements and improved collagen organization
• TB-500: Enhanced cellular migration and actin polymerization in tendon fibroblasts
• GHK-Cu: Increased collagen synthesis and improved tissue remodeling
• KPV: Potential to reduce inflammatory responses that delay tendon healing
• Combined mechanisms suggest comprehensive support for all phases of tendon repair

Studies demonstrated dose-dependent effects with optimal responses observed at 10 mcg/kg for BPC-157 in rodent models, with TB-500 enhancing cellular recruitment and GHK-Cu supporting matrix quality[11].

Muscle Injury Recovery and Regeneration

Component peptide research in muscle injury models revealed complementary healing mechanisms[12]:

• BPC-157: Faster restoration of muscle architecture in crush injury models
• TB-500: Enhanced satellite cell activation and myofiber regeneration
• GHK-Cu: Improved collagen content and reduced fibrosis formation
• KPV: Modulation of inflammatory responses that can impair muscle regeneration
• Combined approach addresses injury repair, cellular recruitment, matrix quality, and inflammation control

Bone and Cartilage Research

Investigations in fracture models demonstrated effects on bone repair processes, including improved callus formation and mineralization, with GHK-Cu’s gene expression effects potentially enhancing osteoblast function[13].

Dermatological and Wound Healing Research

Advanced Skin Regeneration and Scar Reduction

Research on individual components has shown significant effects on dermal wound healing with enhanced outcomes when anti-inflammatory control is included[14]. Findings include:

• Accelerated wound closure rates in multiple animal models across all regenerative components
• KPV-mediated inflammation control: Reduced inflammatory cell infiltration (leukocytes, mast cells)
• Enhanced re-epithelialization and granulation tissue formation
• Improved collagen deposition and organization in healing wounds
• Smaller scar formation demonstrated in KPV studies, complementing tissue repair components
• Antimicrobial effects from KPV against S. aureus and C. albicans

GHK-Cu specifically demonstrated increases in skin thickness, elasticity, and firmness in controlled studies, while BPC-157 showed protective effects against various skin damage models and KPV reduced inflammatory barriers to optimal healing[15].

Hair Follicle Regeneration Research

Preliminary research suggests potential effects on hair follicle development and growth, with thymosin beta-4 research showing accelerated hair growth and GHK-Cu demonstrating follicle support in deficient animal models[16].

Cardiovascular and Vascular Research

Comprehensive Vascular Protection and Repair

Research on component peptides examined effects in various cardiovascular scenarios with complementary mechanisms[17]:

• BPC-157: Improved healing in vascular anastomosis models and arrhythmia protection
• TB-500: Enhanced angiogenesis and collateral circulation development
• GHK-Cu: Support for endothelial function and vascular remodeling
• KPV: Potential to reduce vascular inflammation
• Combined approach supports vessel repair, new vessel formation, and inflammation control

Studies demonstrated cardioprotective effects in ischemia-reperfusion models, with potential synergy between angiogenic promotion and inflammatory modulation.

Respiratory and Airway Research

Pulmonary Inflammation Control

KPV research in airway epithelial cells and lung inflammation demonstrated inhibition of inflammatory signaling in bronchial epithelial cells[18]:

• Suppression of TNF-alpha and viral-induced inflammation
• Reduction of chemokine signaling from airway epithelium
• Potential applications when combined with tissue repair components
• Comprehensive approach to inflammatory lung conditions

KLOW Blend Peptide Pharmacokinetics & Metabolism

Absorption & Distribution

KLOW Blend pharmacokinetics reflect the combined properties of four component peptides, each with distinct absorption and distribution characteristics[19]. Following administration in animal models:

• BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability
• TB-500 shows tissue-specific accumulation with preferential uptake in injured areas
• GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding
• KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues
• Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms

Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms – BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects.

Metabolism & Elimination

The metabolic fate of KLOW Blend involves parallel processing of four distinct peptides[20]:

• BPC-157: Plasma half-life under 30 minutes but biological effects persist for hours to days
• TB-500: Estimated 2-3 hour half-life with C-terminal degradation patterns
• GHK-Cu: Estimated 2-4 hour half-life involving copper release and peptide fragmentation
• KPV: Estimated 1-2 hour half-life with rapid peptidase degradation to amino acids
• Complex interactions between components may influence individual clearance rates
• All components metabolize to amino acids that enter normal metabolic pathways

A significant pharmacokinetic paradox exists across all components: despite rapid plasma clearance (30 minutes to 4 hours), biological effects often persist well beyond plasma elimination, suggesting tissue retention, active metabolite formation, persistent signaling cascade activation, or gene expression changes that outlast peptide presence.

Excretion Pathways

Limited data on combined excretion indicates[21]:

• Primarily renal elimination of peptide fragments from all components
• Hepatic metabolism contributes to overall clearance
• Copper recycling through normal physiological pathways (GHK-Cu component)
• No evidence of accumulation in chronic dosing studies of individual components
• BPC-157 detectable in urine for up to 4 days; other components cleared more rapidly

The relationship between rapid plasma clearance and prolonged biological effects represents a key area requiring further mechanistic investigation across all four components and their potential interactions.

KLOW Blend Research Protocols & Administration

Dosing in Published Research

Research investigations of individual components have employed various dosing strategies that inform potential combination approaches. Common formulations include:

• BPC-157: 10 mg per vial in typical KLOW formulations
• TB-500: 10 mg per vial in typical KLOW formulations
• GHK-Cu: 50 mg per vial in typical KLOW formulations (highest proportion)
• KPV: 10 mg per vial in typical KLOW formulations
• Total blend: 80 mg combined peptide content

Individual component research dosing:

• BPC-157 studies: 10 mcg/kg most common in rat models (range: 1-1000 mcg/kg)
• TB-500 studies: 1-10 mg/kg typical range in rodent research
• GHK-Cu studies: 0.01-100 nanomolar in cell culture; 1-10 mg/kg in animal studies
• KPV studies: 100 micromolar oral concentrations in colitis models; nanomolar in cell culture

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor density, pharmacokinetics, peptide degradation rates, and PepT1 expression patterns. Species-specific factors profoundly influence both efficacy and safety profiles across all four peptide components. The optimal ratios between components for different applications have not been scientifically established through controlled studies.

Administration Routes in Research

Multiple delivery methods have been investigated for component peptides:

• Subcutaneous injection – Most common route for combined formulations in research settings
• Intraperitoneal injection – Used in systemic studies, particularly effective for BPC-157
• Intramuscular injection – Applied in musculoskeletal research protocols
• Oral administration – Uniquely effective for BPC-157 and KPV components unlike most peptides
• Local/topical application – Used in wound healing and dermatological studies
• Transdermal delivery – KPV demonstrated enhanced delivery with iontophoresis and microneedles
• Intravenous injection – Primarily for pharmacokinetic characterization

The combination of BPC-157 and KPV’s oral bioavailability with injectable components creates flexible administration options not available in most peptide formulations.

Common Model Organisms

KLOW Blend Peptide components have been studied across multiple species:

• Rats – Primary research model (Wistar, Sprague-Dawley strains); majority of component data
• Mice – Used for genetic models, IBD research (C57BL/6, BALB/c, MC1R knockout strains), mechanism studies
• Rabbits – Employed in orthopedic, cardiovascular, and fever studies
• Cell culture – Fibroblasts, endothelial cells, keratinocytes, intestinal epithelial cells (Caco2-BBE, HT29), T cells (Jurkat), bronchial epithelial cells, various tissue-specific lines
• Dogs – Limited studies primarily for BPC-157 pharmacokinetics and cardiovascular research
• Ex vivo systems – Human skin explants for transdermal studies

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite extensive research on individual components, KLOW Blend faces substantial translational barriers that limit research utility and prevent any clinical application.

Complete Absence of Human Clinical Data

The most significant limitation is the total lack of human trials for the four-component combination:

• No peer-reviewed human clinical trials exist for KLOW Blend as a formulation
• Individual components have minimal or no human clinical data published
• BPC-157: Zero published human trials despite over 100 preclinical studies
• TB-500: Only one small retrospective human study (12 patients) published
• GHK-Cu: Multiple topical dermatological trials but limited systemic human data
• KPV: No published human clinical trials
• Human safety profile for the four-component combination completely unestablished
• Optimal human dosing ratios and protocols entirely unknown
• Long-term effects in humans totally unstudied

Mechanistic Understanding Gaps

Fundamental aspects of the four-component combination’s mechanism remain unclear:

• Interaction effects between the four peptides incompletely characterized or unstudied
• Whether synergistic, additive, or potentially antagonistic effects occur unknown
• Optimal ratios for different applications not scientifically established through research
• Tissue-specific distribution of combined formulation requires investigation
• Potential for component interference in cellular uptake or activity unstudied
• Whether KPV’s anti-inflammatory effects enhance or potentially limit regenerative signaling unknown
• Competition for cellular resources or transport mechanisms not investigated

Long-Term Safety Considerations

Critical safety questions remain unanswered for the combination:

• Chronic use effects beyond several weeks unstudied even in animals for the combination
• Potential for enhanced growth factor signaling with unknown consequences
• Combined copper delivery, actin modulation, growth signaling, and inflammation suppression effects uncharacterized
• Interaction potential with medications completely uncharacterized for the combination
• Effects on cancer cell growth or tumor progression entirely uninvestigated for four-component formulation
• Reproductive and developmental toxicity of combination inadequately studied
• Immunogenicity potential of four-peptide combination unknown
• Whether chronic inflammation suppression via KPV affects immune competence unstudied

Regulatory & Competitive Sport Status

FDA Position

None of the KLOW Blend components have received FDA approval for human use:

• All four peptides classified as unapproved drug substances by the FDA
• Not recognized as GRAS (Generally Recognized as Safe) individually or in combination
• Not approved for human or veterinary use
• Not legally available for medical compounding in the United States
• No established therapeutic use basis for any component
• BPC-157: FDA warning letters issued regarding human use marketing

The FDA has issued warning letters regarding human use of these peptides, emphasizing their unapproved status and lack of safety and efficacy data.

WADA Prohibition

The World Anti-Doping Agency classifies multiple components as prohibited substances:

• BPC-157: Listed under Section S0 (Non-Approved Substances), prohibited at all times
• TB-500: Listed under S2: Peptide Hormones, Growth Factors, prohibited at all times
• GHK-Cu: Not specifically prohibited but peptide combinations generally scrutinized
• KPV: Not explicitly listed but could fall under similar chemical structure provisions
• No Therapeutic Use Exemptions (TUEs) available for any prohibited components
• Combined formulations would fall under multiple prohibited categories
• Detection methods developed for BPC-157 (up to 4 days) and TB-500

WADA’s prohibition reflects the lack of regulatory approval from health authorities worldwide for these peptides and concerns about tissue-regenerative and performance-enhancing properties.

Research Classification: KLOW Blend is available only for laboratory research purposes. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

Professor Predrag Sikiric has been the primary investigator for BPC-157 research since the 1990s, establishing the foundational research base for one of the key components in KLOW Blend. His laboratory has published over 100 preclinical studies examining BPC-157’s effects across multiple organ systems, contributing significantly to understanding peptide-based tissue repair mechanisms that inform multi-component formulations.

Professor Sikiric’s research contributions include:

• Initial isolation and characterization of BPC-157 from human gastric secretions
• Extensive investigations of gastroprotective and multi-organ tissue healing mechanisms
• Pioneering studies on musculoskeletal tissue repair including tendon, ligament, and muscle healing
• Research on cardiovascular protective effects and vascular injury healing
• Investigations of BPC-157 interactions with nitric oxide pathways and growth factor systems
• Over 100 published papers examining BPC-157’s pleiotropic effects across organ systems

His work has established BPC-157 as one of the most comprehensively studied components in peptide-based regenerative research, though human clinical validation remains completely absent. The foundational research from his laboratory has contributed to the scientific rationale for combination peptide formulations like KLOW Blend, though specific combination studies remain to be conducted.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to peptide research relevant to KLOW Blend peptide components. Cenexa Labs has no affiliation with Professor Sikiric or the University of Zagreb, and this information does not constitute an endorsement of any products or services.

References

1. Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780. PubMed
   
2. Safer, D., Elzinga, M., Nachmias, V.T. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 266(7), 4029-4032. PubMed
   
3. Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H.T., Yan, Y., Sitaraman, S., Merlin, D. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology, 134(1), 166-178. PubMed
   
4. Pickart, L., Margolina, A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. PubMed
   
5. Seiwerth, S., Rucman, R., Turkovic, B., Sever, M., Klicek, R., Radic, B., Drmic, D., Stupnisek, M., Misic, M., Vuletic, L.B., Sikiric, P. (2018). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 24(18), 1972-1989. PubMed
   
6. Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D. (2013). Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design, 20(7), 1126-1135. PubMed
   
7. Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D. (2013). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 19(1), 126-132. PubMed
   
8. Kannengiesser, K., Maaser, C., Heidemann, J., Luegering, A., Ross, M., Brzoska, T., Bohm, M., Luger, T.A., Domschke, W., Kucharzik, T. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324-331. PubMed
   
9. Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., Han, M.K., Kang, Y., Merlin, D. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy, 25(7), 1628-1640. PubMed
   
10. Krivic, A., Anic, T., Seiwerth, S., Huljev, D., Sikiric, P. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research, 24(5), 982-989. PubMed
    
11. Staresinic, M., Sebecic, B., Patrlj, L., Jadrijevic, S., Suknaic, S., Perovic, D., Aralica, G., Zarkovic, N., Borovic, S., Srdjak, M., Hajdar, S., Kopljar, M., Batelja, L., Boban-Blagaic, A., Turcic, I., Amic, F., Ruenzi, E., Rucman, R., Seiwerth, S., Sikiric, P. (2006). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 24(5), 1109-1117. PubMed
    
12. Goldstein, A.L., Hannappel, E., Sosne, G., Kleinman, H.K. (2012). Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37-51. PubMed
    
13. Tkalcevic, V.I., Cuzic, S., Brajsa, K., Mildner, B., Bokulic, A., Situm, K., Perovic, D., Glojnaric, I., Parnham, M.J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology, 570(1-3), 212-221. PubMed
    
14. Brzoska, T., Bohm, M., Lugering, A., Loser, K., Luger, T.A. (2010). Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology, 681, 107-116. PubMed
    
15. Pickart, L., Vasquez-Soltero, J.M., Margolina, A. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, 648108. PubMed
    
16. Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A.L., Kleinman, H.K. (2004). Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development, 125(2), 113-115. PubMed
    
17. Duzel, A., Vlainic, J., Antunovic, M., Malekinusic, D., Vrdoljak, B., Samara, M., Gojkovic, S., Krezic, I., Vidovic, T., Bilic, Z., Sjekavica, I., Djuzel, A.R., Knezevic, M., Sever, A.Z., Lojo, N., Kokot, A., Sever, M., Drmic, D., Seiwerth, S., Sikiric, P. (2017). Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World Journal of Gastroenterology, 23(48), 8465-8488. PubMed
    
18. Land, S.C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Journal of Inflammation Research, 5, 67-77. PubMed
    
19. He, L., Feng, D., Guo, H., Zhou, Y., Li, Z., Zhang, K., Zhang, W., Wang, S., Wang, Z., Hao, Q., Zhang, C., Gao, Y., Gu, J., Zhang, Y., Li, W., Li, M. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 13, 1026182. PubMed
    
20. Ho, E.N., Kwok, W.H., Lau, M.Y., Wong, A.S., Wan, T.S., Lam, K.K., Schiff, P.J., Stewart, B.D. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A, 1265, 57-69. PubMed
    
21. Gwyer, D., Wragg, N.M., Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. KLOW Blend is intended for laboratory research use only.